Algernon Pharmaceuticals Inc C.AGN

Thank you

[Patienceiskee]

To all the great posters on here with your very good information. After double checking with some Associates I feel this could triple with good news. Most of all can save lives. Good luck stay safe

[NamesJeb]

Triple? Depends which trials you predict being successful? If only IPF perhaps only ... 8X. If IPF, chronic cough and covid-19 we're talking anywhere from 8X - 100X. But hey we can all make our own guesstimates!

[Biofinanace]

I will be more than happy to see such multipliers.  Just to correct - So far AGN is running 2 clinical trials  1) COVID - https://clinicaltrials.gov/ct2/show/NCT04382924?term=algernon&draw=2&rank=1 2) IPF & its assoicated cough - https://clinicaltrials.gov/ct2/show/NCT04318704?term=algernon&draw=2&rank=2 AGN has NO clinical trial for chronic cough alone as

[NamesJeb]

My apologies, I wasn't clear. I was more referencing the fact that each of these markets (ipf, chronic cough, and covid-19) have estimated market values forcast over the next 2-5 years. By taking even the smallest of valuations, being IPF at 3.5 billion by 2023 we would arrive at a valuation of aprox 25X if we entirely took over the IPF market alone.

[Algernon]

This post has been removed in accordance with Community Policy

[Biofinanace]

IPF cough is VERY different than cough with underlying disease (acute/chronic, which is where Merck Gefapixant is focusing) ) or no underlying pathogenesis (refracotry cough, which is where Bellus is focusing).  Cough is divided in mainly 4 categories -  1) Acute cough (due to UTRI/COPD/Asthma) may last for 1-3 weeks 2) Sub acute cough (due to postinfection) may last for 3-5 weeks 3

[Algernon]

This post has been removed in accordance with Community Policy